I-AffaMed Therapeutics, inkampani yehlabathi yenqanaba lezonyango ye-biotechnology ezinikele ekuphuhliseni nasekuthengiseni amayeza, idijithali kunye neemveliso zotyando, namhlanje ibhengeze ukuba i-United States yoLawulo lokuTya kunye neDrugs (i-FDA) isicimile isicelo sayo seChiza eNtsha (IND) kuphuhliso lwezonyango. I-AM712 (ASKG712), i-novel proprietary bispecific biologic molekyuli ivala zombini i-vascular endothelial growth factor (VEGF) kunye ne-angiopoietin-2 (Ang-2) yonyango lwezifo ze-retinal vascular.
Ngaphantsi kwale IND, i-AffaMed kungekudala iza kuqalisa isifundo seSigaba soku-1 e-United States ukuphanda ukhuseleko, ukunyamezela, i-pharmacokinetics, kunye nokusebenza kakuhle kwe-AM712 kwizifundo ezine-neovascular AMD.
I-AffaMed Therapeutics isandula kungena kwisivumelwano selayisenisi ne-AskGene Pharma Inc. ngamalungelo akhethekileyo okuphuhlisa, ukwenza kunye nokuthengisa i-AM712 kwiindawo ezazisakuba yi-Asia kunye ne-Japan kwihlabathi jikelele.
"Siyavuya ukusebenzisana ne-AskGene kwaye sifumane imvume yethu yokuqala ye-IND kwi-FDA." UGqr. Dayao Zhao, i-CEO ye-AffaMed uphawule wathi: "Njengenxalenye yesicwangciso sethu se-China-for-Global innovation sokwandisa ubukho obuqinileyo be-AffaMed e-China nase-US ukuqhubela phambili unyango olwahlukileyo kwiimarike zehlabathi, esi sivumelwano selayisensi someleza ngakumbi umbhobho wethu wehlabathi wamehlo. . Ndonwabile ukubona ukuphunyezwa kwethu ngokukhawuleza kwesi sicwangciso sisuka kwilayisensi ukuya kwimvume ye-IND yase-US kwaye sijonge phambili kwintsebenziswano yethu esondeleyo ne-AskGene. "
“I-AskGene izibophelele ekuziseni ngokukhawuleza amayeza akhuselekileyo nasebenzayo kwizigulana ngokusebenzisa ubugcisa obutsha. Sivuyiswa kakhulu ukusebenzisana ne-AffaMed ukuphuhlisa i-anti-VEGF/ANG2 i-bispecific molekyuli ethembisayo i-AMG712(ASKG712) ukuze kuxhamle izigulana” utshilo u-CEO we-AskGene uGqr. Jeff Lu: “Ubuchule obukhethekileyo behlabathi liqela le-AffaMed kwindawo ye-ophthalmology yayiyeyona nto ibalulekileyo ingqalelo ebalulekileyo kwintsebenziswano yethu. Ngokusebenzisana, sinokukhawulezisa uphuhliso lwe-ASKG712 kwihlabathi liphela.
UGqr Ji Li, uMongameli we-AffaMed uthe: "Sikholelwa ukuba i-AM712 inamandla okuba yi-anti-VEGF / Ang-2 bispecific bispecific molecule ye-bispecific bispecific ukujongana neemfuno zonyango ezingafezekanga phakathi kwezigulane ezine-retinal vascular disease. Sichulumancile ukubonisa amandla ethu okusebenza eqinile ekufumaneni imvume ye-IND yase-US kwiinyanga ezi-2 emva kokugqiba isivumelwano sethu selayisenisi kunye no-AskGene. "
